To date, clinically approved ICIs targeting PD-1/PD-L1 and CTLA-4 have shown promising efficacy and became the standard treatments for various cancers, such as advanced melanoma, NSCLC, and solid tumors with microsatellite instability (2, 12, 19). This evidence concerns the gene CTLA4 and cancer.